Fixing the Unfixable: Reissues, Corrections, and the Two-Year Trap -

Last Updated: June 15, 2026 by SK Pulse Editorial Team

In our past analysis, we explored the terrifying reality of the Ex Parte Reexamination—a mechanism that allows your fiercest competitors to pull your granted patent back into the United States Patent and Trademark Office (USPTO) and attack it using old prior art.

But what if the attack isn’t coming from a competitor? What if you are staring at your newly issued, beautifully sealed patent and you suddenly realize you made a terrible mistake?

Perhaps there is a disastrous typo in your chemical formula that renders the patent legally unenforceable. Or worse, perhaps your attorney drafted the legal claims so narrowly that your biggest competitor is currently copying your product without technically infringing the patent.

When your patent is broken from the inside, a Reexamination cannot save you. You must go on a rescue mission. Today, we are breaking down the major post-grant correction procedures, comparing the simple Certificate of Correction with the high-stakes gamble of a Reissue Proceeding, and looking at real USPTO statistics that show exactly how these tools are being weaponized today.

Level 1: The Minor Fix (Certificate of Correction)

Let’s start with the best-case scenario. You receive your granted patent, and upon reading it, you notice a minor error. Perhaps the USPTO accidentally misspelled the inventor’s name, or perhaps your attorney accidentally wrote “10 mm” instead of “100 mm” in the background description.

You do not need a massive legal battle to fix this. You simply need a Certificate of Correction.

Governed by 35 U.S.C. § 254 (for mistakes made by the USPTO) and 35 U.S.C. § 255 (for mistakes made by the applicant), this is an administrative fix. The key limitation here is scope. According to MPEP § 1481, a Certificate of Correction for an applicant’s mistake can only be issued if the error is:

“…of a clerical or typographical nature, or of minor character, and that the correction does not involve such changes in the patent as would constitute new matter or would require reexamination.”

This is a fast, inexpensive process. An examiner does not reopen your file to search for new prior art. The USPTO simply issues a one-page certificate that gets legally stapled to the back of your patent, officially correcting the typo.

Level 2: The Nuclear Option (The Reissue Proceeding)

If your patent contains a massive, substantive error that renders it wholly or partly inoperative or invalid, a Certificate of Correction will be instantly rejected. You must invoke the nuclear option: The Reissue Proceeding.

Unlike a Reexamination (which focuses solely on prior art), a Reissue is a complete “do-over” of the patent to fix an error. According to 35 U.S.C. § 251 and detailed in MPEP § 1401, the USPTO will reissue a patent if it is deemed defective:

“…by reason of the patentee claiming more or less than he had a right to claim in the patent, provided the error was made without any deceptive intention.”

Notice the phrase “without any deceptive intention.” You cannot use a Reissue to fix a lie. You can only use it to fix an honest mistake.

Here is why it is called the nuclear option: You must surrender your original patent. When you file for a Reissue, you literally hand your 20-year monopoly back to the government. The USPTO reopens the entire examination from scratch. They will look at new prior art, re-evaluate your claims, and they can reject everything. If things go terribly wrong, you can lose your patent entirely.

💡 The Financial Cost of a Do-Over: Because a Reissue Proceeding reopens examination, the USPTO treats it financially like a brand-new application. You are responsible for steep new Reissue filing, search, and examination fees. Forecast these exact procedural costs before surrendering your patent using our interactive tool:

Launch the U.S. Patent Filing & Maintenance Fee Estimator (Interactive Calculator)

The Broadening Trap: The Two-Year Absolute Deadline

Why would any inventor take such a massive risk? Usually, it is because they need to broaden their claims.

As we discussed previously, the golden rule of an Ex Parte Reexamination is that you can never broaden a claim. The Reissue proceeding is the only mechanism in U.S. patent law that allows you to expand the scope of your legal monopoly after the patent has been granted.

But the USPTO does not give you unlimited time to realize your mistakes. There is a terrifying, inflexible deadline. According to MPEP § 1412.03:

“A reissue application that broadens the scope of the original patent claims must be filed within two years from the grant of the original patent.”

If you file a Reissue application exactly two years and one day after your patent was granted, your right to broaden your claims is dead forever. You can still file a Reissue to narrow your claims or fix the specification, but the opportunity to expand your monopoly vanishes at the 24-month mark.

The “Recapture” Rule: No Second Chances

If you decide to run the gauntlet of a Broadening Reissue before the two-year deadline, there is one final trap waiting for you: The Recapture Rule.

Imagine that during your original examination three years ago, the examiner rejected your broad claims because they were too close to an old Japanese patent. To get your patent approved, you intentionally deleted the broad claims and accepted narrower ones.

You cannot use a Reissue proceeding to get those broad claims back. The Recapture Rule (MPEP § 1412.02) strictly prohibits an inventor from reclaiming subject matter that they intentionally surrendered to secure the original patent grant. A Reissue is for fixing errors; it is not a tool to change your mind about a strategic compromise you made with the examiner years ago.

By the Numbers: Reissue vs. Reexamination (2021-2025)

To truly understand how the intellectual property market uses these tools, we have to look at the USPTO’s filing statistics over the past five years. The data reveals a fascinating divergence between the defensive Reissue and the aggressive Reexamination.

The Reissue Stability (~600 to 1,000 per year): Reissue filings have remained relatively stable over the last decade. This stability makes sense: Reissues are self-inflicted rescue missions. They correlate directly to the percentage of inventors who realize they made a substantive error and are willing to pay the high fees to fix it. Because it is a voluntary procedure initiated by the patent owner, the numbers rarely spike.
The Reexamination Surge (~300 jumping to 700+ per year): Ex Parte Reexaminations tell a completely different story. Historically hovering around 200 to 300 per year, filings surged massively leading into 2024 and 2025, with recent years seeing well over 700 filings—a jump of more than 60%.

Why the sudden spike? Strategy. In recent years, the primary weapon for attacking patents—the Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB)—has become incredibly expensive and plagued by high procedural denial rates. Competitors and biosimilar companies have realized that Ex Parte Reexaminations are significantly cheaper, carry less procedural risk, and are granted by the USPTO over 90% of the time. The market adapted, shifting its attacks away from the PTAB and directly into the Ex Parte Reexamination queues.

The Takeaway

Your granted patent is a living document, and managing it requires constant vigilance.

If you have a simple typo, file a cheap Certificate of Correction.
If a competitor attacks you with old prior art, prepare for the defensive war of an Ex Parte Reexamination.
But if your claims are fundamentally broken and you need to expand your rights, you must launch a Reissue Proceeding—and you must do it before your strict two-year deadline expires.

Knowing which tool to use, and exactly when the clock runs out, is the difference between a billion-dollar monopoly and a worthless piece of paper.

About the Author & Editorial Policy

SK Pulse Editorial is operated by practitioners with extensive experience navigating international intellectual property frameworks, USPTO post-grant proceedings, and cross-border business operations. The author is a patent law professional coordinating directly with licensed U.S. patent attorneys, but is not a licensed patent attorney, registered patent agent, or legal counsel.

Disclaimer: This article constitutes editorial analysis and is for informational and educational purposes only. It does not constitute formal legal advice or establish an attorney-client relationship. U.S. Patent law, USPTO procedural rules (MPEP), and Code of Federal Regulations (CFR) statutes concerning post-grant proceedings are highly complex. All IP strategy decisions, especially those involving the surrender of a patent via a Reissue Proceeding, should be made in direct consultation with a qualified, licensed intellectual property attorney.